Gain Therapeutics (GANX) Interest & Investment Income (2024 - 2026)

Gain Therapeutics has reported Interest & Investment Income for 3 years, with the latest figure at $61062.0 in Q2 2026.

• On a quarterly basis, Interest & Investment Income rose 43.45% year-over-year to $61062.0 in Q2 2026; TTM through Jun 2026 was $315527.0, a 31.34% increase from a year earlier, with the FY2025 full-year figure at $244394.0, down 31.56% from the prior year.
• Interest & Investment Income was $61062.0 for Q2 2026 at Gain Therapeutics, down from $93052.0 in the prior quarter.
• The five-year high for Interest & Investment Income was $115303.0 in Q1 2024, with the low at $40413.0 in Q1 2025.
• Average Interest & Investment Income over 3 years is $75560.4, with a median of $80706.5 recorded in 2025.
• The sharpest annual moves came in 2025 and 2026: Interest & Investment Income slumped 64.95% in 2025, then jumped 130.25% in 2026.
• Over 3 years, Interest & Investment Income stood at $51857.0 in 2024, then soared by 60.71% to $83339.0 in 2025, then declined by 26.73% to $61062.0 in 2026.
• The last three Interest & Investment Income figures came in at $61062.0 (Q2 2026), $93052.0 (Q1 2026), and $83339.0 (Q4 2025), per Business Quant data.